The Danish laboratory Novo Nordisk has just announced the transfer to Chartres (Eure-et-Loir) of a production line for anti-diabetics manufactured until now in Kalundborg (Denmark). “We export this drug all over the world, except the United States where the group already has a factory,” says Lone Charlotte Larsen, director of the plant in Chartres.
This transfer, which will be completed in July 2022, will not directly create new jobs. On the one hand, the line is highly automated, and the site’s workforce, which is 1,200 employees, excluding temporary workers, does not require job creation, indicates management. But “Novo Nordisk still needs qualified personnel to replace departures and retirements. On average, we are on a wheel of 30 to 50 recruitments per year ”, explains Lone Charlotte Larsen.
250 industrial technicians wanted
By adding other improvements to this new line, the main private employer of Eure-et-Loir will invest 50 million euros. The Chartres plant of this group of 45,000 employees was chosen to produce a new drug indicated in type 2 diabetes, Ozempic. “This class of drugs is experiencing strong growth,” says Lone Charlotte Larsen. The assembly of the injection pens, their packaging with the needles and the packaging will be operational from the start of 2023.
In addition, Novo Nordisk will complete the commissioning of a biomass boiler by the end of the year, for which it has spent 7 million euros. In this department of Eure-et-Loir, located south-west of Paris, which produces medicines and beauty products thanks to the presence of industrialists such as Guerlain, Leo Pharma, Reckitt Bensicker or Puig… the shortage of labor -work is real in factories. For industrial maintenance technicians, companies estimate that there is a shortage of 250 people across the department.